Ganglioside G_Q1b Monoclonal Antibody (Clone CGM3)

Ganglioside G_Q1b is a sialic acid-containing glycosphingolipid that has been found in myelin of the oculomotor nerves and dorsal root ganglia, as well as neuromuscular spindle fibers.^1,2 It is found on the plasma membrane, where it is anchored by the ceramide moiety with the sialylated oligosaccharide on the extracellular side.² In axonal myelin, it helps to stabilize the paranodal region in the node of Ranvier.¹ Ganglioside G_Q1b is similar in shape to lipo-oligosaccharides (LOS) on the membrane of certain pathogens, including the bacterium C. jejuni. Due to this similarity, autoantibodies against ganglioside G_Q1b can be formed during infection with C. jejuni. Ganglioside G_Q1b monoclonal antibody (CGM3) induces muscle fiber twitching then paralysis in ex vivo mouse phrenic nerve hemidiaphragm preparations from mice passively immunized with ganglioside G_Q1b monoclonal antibody (CGM3) but only when human serum is present to provide complement and not when applied alone.² Autoantibodies against ganglioside G_Q1b are found in the cerebrospinal fluid in a majority of patients during the acute phase of Miller-Fisher syndrome, a rare variant of Guillain-Barré syndrome characterized by eye movement abnormalities, impaired coordination, and tendon reflex loss.^2,3,1 Cayman's Ganglioside G_Q1b Monoclonal Antibody (Clone CGM3) binds to Ganglioside G_Q1b Mixture (Item No. 15589) with k_a, k_d, and K_D values of 9,200 M^-1s^-1, 0.0752 s^-1, and 8.18 µM, respectively, as determined by surface plasmon resonance (SPR). It can be used for ELISA, immunofluorescence (IF), and TLC immunostaining applications.

WARNING This product is not for human or veterinary use.

1. Noioso, C.M., Bevilacqua, L., Acerra, G.M., et al. Miller Fisher syndrome: An updated narrative review. Front. Neurol. 14, 1250774 (2023).

2. Goodyear, C.S., O'Hanlon, G.M., Plomp, J.J., et al. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J. Clin. Invest. 104(6), 697-708 (1999).

3. Halstead, S.K., Humphreys, P.D., Goodfellow, J.A., et al. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann. Neurol. 58(2), 203-210 (2005).